Inhibikase Therapeutics, Inc. announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | -3.31% |
|
-17.02% | -7.87% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.87% | 8.73M | |
+18.86% | 44.87B | |
-10.26% | 37.8B | |
+40.32% | 37.61B | |
+29.49% | 31.32B | |
-8.44% | 27.4B | |
+13.03% | 26.32B | |
+43.60% | 14.07B | |
+31.69% | 12.5B | |
-5.99% | 11.23B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib